scholarly journals Total femur replacement for Ewing’s sarcoma after wide resection of the proximal femur: a long-term follow-up case study

2011 ◽  
Vol 5 (1) ◽  
pp. 119-122
Author(s):  
Yukihiro Yoshida ◽  
Shunzo Osaka ◽  
Yasuaki Tokuhashi
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Tumor Resection ◽  
Wide Resection ◽  
Long Term Follow Up ◽  
And Migration ◽  
The Right

Abstract Background: Total femur replacement is a relatively rarely performed procedure for the reconstruction of an affected limb after resection of a malignant bone tumor. Objective: Report total femur replacement in a 17-year-old male patient after wide resection of the right femur for involvement of the proximal segment of the bone by Ewing’s sarcoma. Results: The complications that often arose from the use of the tumor prostheses after the tumor resection, e.g., infection and migration/dislocation of the artificial bonehead, were overcome successfully. The patient has been under follow-up for a relatively long period of time (16 years) since the surgery. The operated limb function is now rated at 70% according to the rating system by Musculo-Skeletal Tumor Society (MSTS). The patient has almost completely regained his ability to walk and carries on with activities of daily living. Conclusion: If appropriate measures are taken to deal with the complications, favorable function of the operated limb can be expected to be maintained for long periods after reconstruction using this technique.

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

1990 ◽  
Vol 8 (10) ◽  
pp. 1664-1674 ◽  
Author(s):  
M E Nesbit ◽  
E A Gehan ◽  
E O Burgert ◽  
T J Vietti ◽  
A Cangir ◽  
...  
Keyword(s):  
Overall Survival ◽  
Local Recurrence ◽  
Multimodal Therapy ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Patient Characteristics ◽  
Group I ◽  
Long Term Follow Up

A total of 342 previously untreated eligible children were entered into the first Intergroup Ewing's Sarcoma Study (IESS) between May 1973 and November 1978. In group I institutions, patients were randomized between treatment 1 (radiotherapy to primary lesion plus cyclophosphamide, vincristine, dactinomycin, and Adriamycin [doxorubicin; Adria Laboratories, Columbus, OH] [VAC plus ADR]) or treatment 2 (same as treatment 1 without ADR), and group II institutions randomized patients between treatment 2 or treatment 3 (same as treatment 2 plus bilateral pulmonary radiotherapy [VAC plus BPR]). The percentages of patients relapse-free and surviving (RFS) at 5 years for treatments 1, 2, and 3 were 60%, 24%, and 44%, respectively. There was strong statistical evidence of a significant advantage in RFS for treatment 1 (VAC plus ADR) versus 2 (VAC alone) (P less than .001) and 3 (P less than .05) and also of treatment 3 versus 2 (P less than .001). Similar significant results were observed with respect to overall survival. Patients with disease at pelvic sites have significantly poorer survival at 5 years than those with disease at nonpelvic sites (34% v 57%; P less than .001). Among pelvic cases, there was no evidence of differing survival by treatment (P = .81), but among nonpelvic cases, there was strong evidence of differing survival by treatment (P less than .001). The overall percentage of patients developing metastatic disease was 44%; the percentages by treatments 1, 2, and 3 were 30%, 72%, and 42%, respectively. The overall incidence of local recurrence was 15%, and there was no evidence that local recurrence rate differed by treatment. Patient characteristics related to prognosis, both with respect to RFS and overall survival experience, were primary site (nonpelvic patients were most favorable) and patient age (younger patients were more favorable).

Ewing's sarcoma: Long-term follow-up in 49 patients treated from 1967 to 1989

1993 ◽  
Vol 25 (3) ◽  
pp. 431-438 ◽  
Author(s):  
Hedy Mameghan ◽  
Richard J. Fisher ◽  
Darcy O'Gorman-Hughes ◽  
Edward H. Bates ◽  
Ronald L. Huckstep ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Long Term Follow Up

scholarly journals Long-Term Follow-Up of Adamantinoma of the Tibia Complicated by Metastases and a Second Unrelated Primary Cancer: A Case Report and Literature Review

2018 ◽  
Vol 2018 ◽  
pp. 1-9
Author(s):  
Brendan R. Southam ◽  
Alvin H. Crawford ◽  
David A. Billmire ◽  
James Geller ◽  
Daniel Von Allmen ◽  
...  
Keyword(s):  
Inguinal Lymph Node ◽  
Lower Lobe ◽  
Wide Resection ◽  
Low Grade ◽  
Long Bones ◽  
Primary Cancer ◽  
Long Term Follow Up ◽  
The Right

Adamantinoma is a rare, low-grade malignant tumor of the bone which grows slowly and typically occurs in the diaphysis of long bones, particularly in the tibia. Adamantinomas have the potential for local recurrence and may metastasize to the lungs, lymph nodes, or bone. We report a case of a 14-year-old female with a tibial adamantinoma who underwent wide resection with limb salvage and has subsequently been followed up for 18 years. The patient went on to have both a local soft tissue recurrence 5 years after the resection and metastases to both an inguinal lymph node and the right lower lobe of the lung 8 years after that recurrence, all of which have been treated successfully with marginal resections. Unique to this case, the patient was also incidentally found to have chromophobe-type renal cell carcinoma when undergoing a partial nephrectomy to resect a presumed metastasis of her adamantinoma. Genetic testing has not revealed any known genetic predisposition to cancer.

scholarly journals Outcome of Ewing's sarcoma of the scapula–a long-term follow-up study

2020 ◽  
Vol 106 (1) ◽  
pp. 25-30
Author(s):  
Shahbaz S. Malik ◽  
Muaaz Tahir ◽  
Usman Ahmed ◽  
Scott Evans ◽  
Lee Jeys ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Follow Up Study ◽  
Long Term Follow Up

Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma.

1988 ◽  
Vol 6 (1) ◽  
pp. 76-82 ◽  
Author(s):  
T J Stillwell ◽  
R C Benson ◽  
E O Burgert
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Hemorrhagic Cystitis ◽  
Significant Loss ◽  
Gross Hematuria ◽  
Primary Surgery ◽  
Cyclophosphamide Treatment ◽  
Long Term Follow Up

Recent improvements in survival of patients with Ewing's sarcoma have been made since the addition of cyclophosphamide-based adjuvant chemotherapy to primary surgery and radiation. A potential limitation to cyclophosphamide use is its urotoxicity, primarily in the form of hemorrhagic cystitis. The incidence of this adverse effect in patients treated for Ewing's sarcoma has not been established. In a Mayo Clinic series of 116 patients with Ewing's sarcoma treated with cyclophosphamide, 17 (15%) developed hemorrhagic cystitis diagnosed on the basis of gross hematuria or cystoscopic findings (or both). Microscopic hematuria also occurred in 53% of patients (56 of 105 examined). The dose and duration of therapy appeared to be unrelated to the development of urotoxicity. Most patients recovered uneventfully with or without discontinuation of cyclophosphamide therapy, but a significant loss of blood occurred in three patients, and one patient required a cystectomy because of bladder fibrosis. Long-term follow-up is mandatory in these patients because of late recurrences of hemorrhagic cystitis or the possibility of bladder carcinoma. New therapies, directed at protecting the bladder from urotoxicity during cyclophosphamide treatment, are available.

Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy

1991 ◽  
Vol 20 (3) ◽  
pp. 389-395 ◽  
Author(s):  
Timothy J. Kinsella ◽  
James S. Miser ◽  
Brenda Waller ◽  
David Venzon ◽  
Eli Glatstein ◽  
...  
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Combined Modality Therapy ◽  
Combined Modality ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document